FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Loewen Andrea
2. Date of Event Requiring Statement (MM/DD/YYYY)
2/7/2022 

3. Issuer Name and Ticker or Trading Symbol

REATA PHARMACEUTICALS INC [RETA]
(Last)        (First)        (Middle)

5320 LEGACY DRIVE
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
SVP, Global Regulatory Affairs /
(Street)

PLANO, TX 75024      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Class A common stock 32856 (1)D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (right to buy)  (2)2/24/2030 Class A common stock 11250 $196.23 D  
Employee Stock Option (right to buy)  (3)1/4/2031 Class A common stock 9000 $121.29 D  
Employee Stock Option (right to buy)  (4)1/3/2032 Class A common stock 50000 $27.32 D  

Explanation of Responses:
(1) The shares represent 543 shares of Class A common stock; 750 Restricted Stock Units (RSU), which vest in equal installments on April 26, 2022, April 26, 2023, and April 26, 2024, subject to continued service through each vesting date; 4,500 RSUs, which vest in equal installments on March 6, 2022, March 6, 2023, March 6, 2024, and March 6, 2025, subject to continued service through each vesting date; 2,250 RSUs, which vest in equal installments on March 1, 2022, March 1, 2023, and March 1, 2024, subject to continued service through each vesting date; and 25,000 RSUs, which vest in equal installments on March 6, 2023, March 6, 2024, March 6, 2025, and March 6, 2026, subject to continued service through each vesting date.
(2) The options vest 25% on February 24, 2021 and in 12 equal quarterly installments thereafter, subject to continued service through each vesting date.
(3) The options vest in sixteen equal quarterly installments beginning on April 4, 2021, subject to continued service through each vesting date.
(4) The options vest in sixteen equal quarterly installments beginning on April 3, 2022, subject to continued service through each vesting date.

Remarks:
Exhibit List: Exhibit 24 - Power of Attorney

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Loewen Andrea
5320 LEGACY DRIVE
PLANO, TX 75024


SVP, Global Regulatory Affairs

Signatures
/s/ Tracy Herson, attorney-in-fact2/7/2022
**Signature of Reporting PersonDate

Reata Pharmaceuticals (NASDAQ:RETA)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Reata Pharmaceuticals Charts.
Reata Pharmaceuticals (NASDAQ:RETA)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Reata Pharmaceuticals Charts.